INOVIO PHARMACEUTICALS, INC. Operating Lease, Right-of-Use Asset, Amortization Expense
INOVIO PHARMACEUTICALS, INC. (INO) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $872.47 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-12
- INOVIO PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $443.85K, a 15.13% increase year-over-year.
- INOVIO PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $428.62K, a 15.19% increase year-over-year.
- INOVIO PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $413.86K, a 15.28% increase year-over-year.
- INOVIO PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $399.46K, a 15.27% increase year-over-year.
- INOVIO PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $1.57M, a 14.01% increase from fiscal 2024.
- INOVIO PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $1.38M, a 87.09% increase from fiscal 2023.
- INOVIO PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $736.47K, a 45.15% decline from fiscal 2022.
- INOVIO PHARMACEUTICALS, INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $1.34M, a 14.74% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $443.85K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $872.47K 10-Q · filed 2026-08-12 | $1.29M derived: sum of 3 quarters · filed 2026-08-12 | $1.69M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $428.62K 10-Q · filed 2026-05-13 | $842.48K derived: sum of 2 quarters · filed 2026-05-13 | $1.24M derived: sum of 3 quarters · filed 2026-05-13 | $1.63M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $413.86K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $813.32K derived: sum of 2 quarters · filed 2026-03-12 | $1.20M derived: sum of 3 quarters · filed 2026-08-12 | $1.57M 10-K · filed 2026-03-12 |
| 2025-09-30 | $399.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $784.98K derived: sum of 2 quarters · filed 2026-08-12 | $1.16M 10-Q · filed 2025-11-10 | $1.52M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $385.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $757.60K 10-Q · filed 2026-08-12 | $1.12M derived: sum of 3 quarters · filed 2026-08-12 | $1.46M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $372.08K 10-Q · filed 2026-05-13 | $731.09K derived: sum of 2 quarters · filed 2026-05-13 | $1.08M derived: sum of 3 quarters · filed 2026-05-13 | $1.41M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $359.01K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $705.56K derived: sum of 2 quarters · filed 2026-03-12 | $1.04M derived: sum of 3 quarters · filed 2026-03-12 | $1.38M 10-K · filed 2026-03-12 |
| 2024-09-30 | $346.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $683.63K derived: sum of 2 quarters · filed 2025-11-10 | $1.02M 10-Q · filed 2025-11-10 | $624.43K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $337.08K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $672.34K 10-Q · filed 2025-08-12 | $277.88K derived: sum of 3 quarters · filed 2025-08-12 | $669.34K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $335.26K 10-Q · filed 2025-05-13 | -$59.20K derived: sum of 2 quarters · filed 2025-05-13 | $332.26K derived: sum of 3 quarters · filed 2025-05-13 | $709.07K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$394.46K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$3.00K derived: sum of 2 quarters · filed 2025-03-18 | $373.81K derived: sum of 3 quarters · filed 2025-03-18 | $736.47K 10-K · filed 2025-03-18 |
| 2023-09-30 | $391.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $768.27K derived: sum of 2 quarters · filed 2024-11-14 | $1.13M 10-Q · filed 2024-11-14 | $1.48M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $376.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $739.47K 10-Q · filed 2024-08-08 | $1.09M derived: sum of 3 quarters · filed 2024-08-08 | $1.42M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $362.66K 10-Q · filed 2024-05-13 | $711.53K derived: sum of 2 quarters · filed 2024-05-13 | $1.05M derived: sum of 3 quarters · filed 2024-05-13 | $1.39M derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $348.87K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $684.32K derived: sum of 2 quarters · filed 2024-03-06 | $1.02M derived: sum of 3 quarters · filed 2024-03-06 | $1.34M 10-K · filed 2024-03-06 |
| 2022-09-30 | $335.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $674.36K derived: sum of 2 quarters · filed 2023-11-09 | $993.95K 10-Q · filed 2023-11-09 | $1.30M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $338.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $658.50K 10-Q · filed 2023-08-09 | $965.71K derived: sum of 3 quarters · filed 2024-03-06 | $1.26M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $319.59K 10-Q · filed 2023-05-10 | $626.80K derived: sum of 2 quarters · filed 2024-03-06 | $921.97K derived: sum of 3 quarters · filed 2024-03-06 | $1.21M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $307.21K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $602.39K derived: sum of 2 quarters · filed 2024-03-06 | $891.98K derived: sum of 3 quarters · filed 2024-03-06 | $1.17M 10-K · filed 2024-03-06 |
| 2021-09-30 | $295.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $584.77K derived: sum of 2 quarters · filed 2022-11-08 | $863.06K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $289.59K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $567.88K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $278.29K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $1.04M 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |